http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
MEI Pharma (MEIP) says FDA informed the companies of its position that a randomized trial is now needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates
-
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
-
MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
-
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments
-
Pre-Open Stock Movers 02/03: (ZEV) (TMUS) (HUM) Higher; (FB) (SNAP) (SPOT) Lower (more...)
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma (MEIP) and Kyowa Kirin Reports Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib
-
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
-
MEI Pharma (MEIP) to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
-
MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
-
MEI Pharma (MEIP) Appoints Biotechnology Executive Sujay Kango to its Board of Directors
-
MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors
-
MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights
-
MEI Pharma (MEIP) and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
-
MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
-
MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights
-
MEI Pharma to Present at Two Healthcare Conferences
-
MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021
-
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
-
MEI Pharma (MEIP) Announces CFO Retirement
-
MEI Pharma Announces Planned Chief Financial Officer Transition
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
-
MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting
-
MEI Pharma (MEIP) and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-
MEI Pharma (MEIP), Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
-
MEI Pharma (MEIP) Announces Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer
-
MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer
-
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers
-
MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference
-
MEI Pharma to present at the virtual H.C. Wainwright Global Life Sciences Conference 2021
-
MEI Pharma (MEIP) Reports Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
-
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
-
MEI Pharma (MEIP), Helsinn Group Discontinue Ph. 3 Study with Pracinostat in AML after Completing Interim Analysis
-
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
-
MEI Pharma (MEIP), Helsinn Report Updated Clinical Data from Ph. 2 Study Evaluating Pracinostat in Combination with Azacitidine
-
Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes
